Home > Resources > Whitepapers > Trends in the Biosimilars Market

Trends in the Biosimilars Market

May 17, 2018

Despite biosimilars being available for over ten years in some markets, the biosimilars market continues to evolve. Development of biosimilars is a truly global endeavour, helped by the spread of regulatory guidance. In this white paper, we explore the biosimilar R&D landscape, physician attitudes towards biosimilars, and drivers to prescribe, as well as two case studies on the launch dynamics of Sandoz’s Zarxio and Pfizer’s Inflectra in the United States.

Spotlight

Metabolomic Diagnostics Ltd

Metabolomic Diagnostics Ltd. is an innovative biotechnology company developing groundbreaking pregnancy risk stratification tests, through the use of metabolomic profiling. The company is currently developing an early pregnancy test to identify a woman's risk of developing pre-eclampsia later in her pregnancy.

OTHER WHITEPAPERS

Use of PS-DVB Columns and Matched Buffers in the Purification and Scale-Up of mRNA Drug Candidates

whitePaper | August 24, 2022

The validity of mRNA as an approved pharmaceutical is now largely accepted, with the historic launch and administration of billions of doses of mRNA Covid vaccines (1).

U.S. NATIONAL SCIENCE FOUNDATION

whitePaper | August 21, 2022

The “Government Performance and Results Act” and the “GPRA Modernization Act of 2010 require federal agencies to develop strategic plans setting forth long-term goals and objectives. Guidance.

2022 Global Life Sciences Outlook

whitePaper | January 7, 2022

While valuations for the life sciences sector in this past year have been mixed, the underlying performance and outlook for the sector is healthy

Application of Single-Use Technologies(SUT) in Biosimilar Development

whitePaper | December 20, 2022

The current processing paradigm of large manufacturing facilities dedicated to singleproduct production is no longer an effective approach for best manufacturing practices.

Cell and Gene Therapy Hot Buttons Series

whitePaper | September 27, 2022

Cell and Gene Therapy (CAGT) activity has increased dramatically in recent decades, especially in Chimeric Antigen Receptor T-Cell (CAR-T) clinical trials and therapy registrations. The IQVIA CAGT Hot Buttons series covers basic concepts in CAGT for newcomers to this field.

More Whitepapers